NCT06938750 Novel Medical Device for Pharmacological Therapy
| NCT ID | NCT06938750 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fundacion Miguel Servet |
| Condition | Vascular Access |
| Study Type | INTERVENTIONAL |
| Enrollment | 262 participants |
| Start Date | 2023-01-20 |
| Primary Completion | 2026-01-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 262 participants in total. It began in 2023-01-20 with a primary completion date of 2026-01-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Background: Different co-creation methods were used to design and prototype a new fixative device for multiple intravenous therapies with the ability to control and identify the pharmacological therapy administered to a patient. Objectives: To validate a newly created device for the reduction of complications related to the use of intravenous therapy Methods: A multidisciplinary team composed of eight professionals specializing in the field of critical care and an engineering professional in industrial design was responsible for collecting, evaluating, and materializing the ideas and needs arising from clinical practice in a device that met the standards of the same.
Eligibility Criteria
Inclusion Criteria: * patients admitted to the intensive care unit * patients with authorization to take part in the study Exclusion Criteria: * Patients with pre-existing medical conditions: Patients with diseases affecting coagulation, such as hemophilia or thrombocytopathies, could be excluded. * Active infection patients: Any patient with vascular access site infections or systemic infections may be excluded to avoid complications. * Inability to give informed consent: Patients who are unable to understand or consent to participate in the study.
Contact & Investigator
Marta M Ferraz-Torres, PHD
PRINCIPAL INVESTIGATOR
Fundación Miguel Servet
Frequently Asked Questions
Who can join the NCT06938750 clinical trial?
This trial is open to participants of all sexes, aged 1 Year or older, studying Vascular Access. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06938750 currently recruiting?
Yes, NCT06938750 is actively recruiting participants. Contact the research team at marta.ferraz.torres@navarra.es for enrollment information.
Where is the NCT06938750 trial being conducted?
This trial is being conducted at Pamplona, Spain.
Who is sponsoring the NCT06938750 clinical trial?
NCT06938750 is sponsored by Fundacion Miguel Servet. The principal investigator is Marta M Ferraz-Torres, PHD at Fundación Miguel Servet. The trial plans to enroll 262 participants.